GeneDx (WGS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

WGS Stock Forecast

GeneDx stock forecast is as follows: an average price target of $42.50 (represents a -40.23% downside from WGS’s last price of $71.10) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

WGS Price Target

The average price target for GeneDx (WGS) is $42.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $21.00. This represents a potential -40.23% downside from WGS's last price of $71.10.

WGS Analyst Ratings

Buy

According to 4 Wall Street analysts, GeneDx's rating consensus is 'Buy'. The analyst rating breakdown for WGS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

GeneDx Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 24, 2024	Bill Bonello	Craig-Hallum	$70.00	$58.00	20.69%	-1.55%
Aug 27, 2024	Brandon Couillard	Wells Fargo	$34.00	$35.35	-3.82%	-52.18%
Jul 31, 2024	Mark Massaro	BTIG	$45.00	$30.13	49.35%	-36.71%
Jul 10, 2024	Bill Bonello	Craig-Hallum	$43.00	$29.81	44.25%	-39.52%
Jun 26, 2024	Mark Massaro	BTIG	$35.00	$26.19	33.64%	-50.77%
Jun 03, 2024	Tycho Peterson	Jefferies	$21.00	$19.61	7.09%	-70.46%
Apr 30, 2024	Mark Massaro	BTIG	$19.00	$11.00	72.73%	-73.28%

Row per page

Go to

The latest GeneDx stock forecast, released on Oct 24, 2024 by Bill Bonello from Craig-Hallum, set a price target of $70.00, which represents a 20.69% increase from the stock price at the time of the forecast ($58.00), and a -1.55% decrease from WGS last price ($71.10).

GeneDx Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	7
Avg Price Target	$70.00	$52.00	$38.14
Last Closing Price	$71.10	$71.10	$71.10
Upside/Downside	-1.55%	-26.86%	-46.36%

In the current month, the average price target of GeneDx stock is $70.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -1.55% decrease as opposed to GeneDx's last price of $71.10. This month's average price target is up 34.62% compared to last quarter, and up 83.53% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Wells Fargo	Equal-Weight	Equal-Weight	Hold
Oct 29, 2024	BTIG	Buy	Buy	Hold
Oct 24, 2024	Craig-Hallum	Buy	Buy	Hold
Aug 27, 2024	Wells Fargo	-	Equal-Weight	Initialise
Jul 31, 2024	Craig-Hallum	Buy	Buy	Hold
Jul 31, 2024	Cowen & Co.	Buy	Buy	Hold
Jul 31, 2024	BTIG	Buy	Buy	Hold
Jul 10, 2024	Craig-Hallum	-	Buy	Initialise
Jun 26, 2024	BTIG	Buy	Buy	Hold
Apr 30, 2024	Cowen & Co.	Buy	Buy	Hold

Row per page

Go to

GeneDx's last stock rating was published by Wells Fargo on Oct 29, 2024. The company gave WGS a "Equal-Weight" rating, the same as its previous rate.

GeneDx Financial Forecast

GeneDx Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$43.14M	$61.35M	$83.23M	$36.17M	$53.94M	$57.80M	$43.18M
Avg Forecast	$108.23M	$100.57M	$99.77M	$81.43M	$90.88M	$85.52M	$82.76M	$77.80M	$80.22M	$64.98M	$59.31M	$49.45M	$54.24M	$52.42M	$47.59M	$40.14M	$70.96M	$67.74M	$67.55M	$47.50M	$49.67M	$42.67M
High Forecast	$109.83M	$102.06M	$101.25M	$82.64M	$92.23M	$86.79M	$83.99M	$78.95M	$81.41M	$65.06M	$59.31M	$49.45M	$55.05M	$55.41M	$48.29M	$40.74M	$72.01M	$67.74M	$67.55M	$47.50M	$49.67M	$42.67M
Low Forecast	$105.47M	$98.01M	$97.23M	$79.35M	$88.57M	$83.34M	$80.65M	$75.82M	$78.17M	$64.90M	$59.31M	$49.45M	$52.86M	$48.01M	$46.37M	$39.12M	$69.15M	$67.74M	$67.55M	$47.50M	$49.67M	$42.67M
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	1	4	2	2	1	1	1	1	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07%	0.86%	1.23%	0.54%	1.14%	1.16%	1.01%

GeneDx's average Quarter revenue forecast for Jun 23 based on 2 analysts is $47.59M, with a low forecast of $46.37M, and a high forecast of $48.29M. WGS's average Quarter revenue forecast represents a 10.31% increase compared to the company's last Quarter revenue of $43.14M (Mar 23).

GeneDx EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	1	4	2	2	1	1	1	1	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-46.16M	$-79.56M	$-79.32M	$-153.25M	$-83.47M	$-33.92M	$37.57M
Avg Forecast	$-82.00M	$-76.20M	$-75.59M	$-61.70M	$-68.86M	$-64.80M	$-62.71M	$-58.95M	$-60.78M	$-49.23M	$-44.94M	$-37.47M	$-41.10M	$-39.72M	$-36.05M	$-30.42M	$-53.77M	$-50.75M	$-50.61M	$-35.59M	$-37.21M	$-31.97M
High Forecast	$-79.91M	$-74.26M	$-73.67M	$-60.13M	$-67.11M	$-63.14M	$-61.11M	$-57.45M	$-59.23M	$-49.17M	$-44.94M	$-37.47M	$-40.05M	$-36.37M	$-35.14M	$-29.64M	$-52.40M	$-50.75M	$-50.61M	$-35.59M	$-37.21M	$-31.97M
Low Forecast	$-83.22M	$-77.33M	$-76.71M	$-62.61M	$-69.88M	$-65.76M	$-63.64M	$-59.82M	$-61.68M	$-49.30M	$-44.94M	$-37.47M	$-41.71M	$-41.98M	$-36.59M	$-30.87M	$-54.56M	$-50.75M	$-50.61M	$-35.59M	$-37.21M	$-31.97M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.52%	1.48%	1.56%	3.03%	2.35%	0.91%	-1.18%

2 analysts predict WGS's average Quarter EBITDA for Dec 21 to be $-37.21M, with a high of $-37.21M and a low of $-37.21M. This is -199.05% lower than GeneDx's previous annual EBITDA (Sep 21) of $37.57M.

GeneDx Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	1	4	2	2	1	1	1	1	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-60.99M	$-308.76M	$-77.58M	$-85.74M	$-64.49M	$-41.13M	$31.39M
Avg Forecast	-	-	-	-	$4.61M	$3.86M	$2.51M	$1.63M	$2.91M	$-5.83M	$-8.13M	$-18.06M	$-17.70M	$-35.50M	$-35.59M	$-42.64M	$-164.86M	$-181.53M	$-180.07M	$-281.09M	$-226.24M	$-163.97M
High Forecast	-	-	-	-	$4.70M	$3.94M	$2.55M	$1.66M	$2.97M	$-5.63M	$-7.86M	$-17.47M	$-17.12M	$-31.97M	$-34.41M	$-41.22M	$-159.40M	$-181.53M	$-180.07M	$-281.09M	$-226.24M	$-163.97M
Low Forecast	-	-	-	-	$4.45M	$3.73M	$2.42M	$1.57M	$2.82M	$-5.94M	$-8.29M	$-18.41M	$-18.04M	$-39.56M	$-36.27M	$-43.46M	$-168.04M	$-181.53M	$-180.07M	$-281.09M	$-226.24M	$-163.97M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.43%	1.87%	0.43%	0.48%	0.23%	0.18%	-0.19%

GeneDx's average Quarter net income forecast for Dec 21 is $-226.24M, with a range of $-226.24M to $-226.24M. WGS's average Quarter net income forecast represents a -820.71% decrease compared to the company's last Quarter net income of $31.39M (Sep 21).

GeneDx SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	1	4	2	2	1	1	1	1	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$57.14M	$72.44M	$89.31M	$104.15M	$72.33M	$100.85M	$55.35M
Avg Forecast	$111.90M	$103.98M	$103.15M	$84.19M	$93.96M	$88.42M	$85.57M	$80.44M	$82.94M	$67.18M	$61.32M	$51.13M	$56.08M	$54.19M	$49.20M	$41.50M	$73.37M	$68.08M	$67.89M	$47.74M	$49.92M	$42.89M
High Forecast	$113.56M	$105.52M	$104.68M	$85.44M	$95.36M	$89.73M	$86.84M	$81.63M	$84.17M	$67.27M	$61.32M	$51.13M	$56.91M	$57.29M	$49.93M	$42.12M	$74.46M	$68.08M	$67.89M	$47.74M	$49.92M	$42.89M
Low Forecast	$109.05M	$101.33M	$100.52M	$82.04M	$91.57M	$86.16M	$83.39M	$78.39M	$80.82M	$67.10M	$61.32M	$51.13M	$54.65M	$49.63M	$47.94M	$40.45M	$71.50M	$68.08M	$67.89M	$47.74M	$49.92M	$42.89M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.38%	0.99%	1.31%	1.53%	1.52%	2.02%	1.29%

GeneDx's average Quarter SG&A projection for Jun 23 is $49.20M, based on 2 Wall Street analysts, with a range of $47.94M to $49.93M. The forecast indicates a -13.90% fall compared to WGS last annual SG&A of $57.14M (Mar 23).

GeneDx EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	3	3	1	1	1	1	4	2	2	1	1	1	1	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.04	$-2.86	$-0.20	$-0.25	$-0.26	$-0.17	$0.17
Avg Forecast	-	-	-	-	$0.17	$0.14	$0.09	$0.06	$0.11	$-0.21	$-0.30	$-0.67	$-0.65	$-1.31	$-1.31	$-1.57	$-6.08	$-6.82	$-6.76	$-10.56	$-8.50	$-6.16
High Forecast	-	-	-	-	$0.17	$0.15	$0.09	$0.06	$0.11	$-0.21	$-0.29	$-0.64	$-0.63	$-1.18	$-1.27	$-1.52	$-5.88	$-6.82	$-6.76	$-10.56	$-8.50	$-6.16
Low Forecast	-	-	-	-	$0.16	$0.14	$0.09	$0.06	$0.10	$-0.22	$-0.31	$-0.68	$-0.67	$-1.46	$-1.34	$-1.60	$-6.20	$-6.82	$-6.76	$-10.56	$-8.50	$-6.16
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.93%	0.47%	0.03%	0.04%	0.02%	0.02%	-0.03%

According to 2 Wall Street analysts, GeneDx's projected average Quarter EPS for Dec 21 is $-8.50, with a low estimate of $-8.50 and a high estimate of $-8.50. This represents a -5099.82% decrease compared to WGS previous annual EPS of $0.17 (Sep 21).

GeneDx Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BBLN	Babylon	$0.55	$5.50	900.00%	Buy
AKLI	Akili	$0.43	$3.25	655.81%	Buy
DH	Definitive Healthcare	$4.12	$9.50	130.58%	Hold
CERT	Certara	$9.99	$19.33	93.49%	Buy
HCTI	Healthcare Triangle	$1.14	$2.00	75.44%	Buy
PRVA	Privia Health Group	$20.95	$33.82	61.43%	Buy
HSTM	HealthStream	$31.31	$29.00	-7.38%	Buy
WGS	GeneDx	$71.10	$42.50	-40.23%	Buy

WGS Forecast FAQ

Is GeneDx a good buy?

Yes, according to 4 Wall Street analysts, GeneDx (WGS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of WGS's total ratings.

What is WGS's price target?

GeneDx (WGS) average price target is $42.5 with a range of $21 to $70, implying a -40.23% from its last price of $71.1. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will GeneDx stock go up soon?

According to Wall Street analysts' prediction for WGS stock, the company can go down by -40.23% (from the last price of $71.1 to the average price target of $42.5), down by -1.55% based on the highest stock price target, and down by -70.46% based on the lowest stock price target.

Can GeneDx stock reach $110?

WGS's average twelve months analyst stock price target of $42.5 does not support the claim that GeneDx can reach $110 in the near future.

What is GeneDx's current price target trend?

1 Wall Street analyst forecast a $70 price target for GeneDx (WGS) this month, down -1.55% from its last price of $71.1. Compared to the last 3 and 12 months, the average price target decreased by -26.86% and decreased by -46.36%, respectively.

What are GeneDx's analysts' financial forecasts?

GeneDx's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $336.96M (high $341.96M, low $328.37M), average EBITDA is $-255M (high $-249M, low $-259M), average net income is $12.6M (high $12.84M, low $12.18M), average SG&A $348.38M (high $353.55M, low $339.51M), and average EPS is $0.465 (high $0.474, low $0.45). WGS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $390M (high $395.78M, low $380.06M), average EBITDA is $-295M (high $-288M, low $-300M), average net income is $0 (high $0, low $0), average SG&A $403.22M (high $409.2M, low $392.95M), and average EPS is $0 (high $0, low $0).

Did the WGS's actual financial results beat the analysts' financial forecasts?

Based on GeneDx's last annual report (Dec 2022), the company's revenue was $234.69M, which missed the average analysts forecast of $253.76M by -7.51%. Apple's EBITDA was $-396M, beating the average prediction of $-191M by 107.44%. The company's net income was $-549M, missing the average estimation of $-808M by -32.02%. Apple's SG&A was $338.24M, beating the average forecast of $257.09M by 31.57%. Lastly, the company's EPS was $-5.08, missing the average prediction of $-30.229 by -83.20%. In terms of the last quarterly report (Mar 2023), GeneDx's revenue was $43.14M, beating the average analysts' forecast of $40.14M by 7.46%. The company's EBITDA was $-46.16M, beating the average prediction of $-30.416M by 51.76%. GeneDx's net income was $-60.989M, beating the average estimation of $-42.636M by 43.05%. The company's SG&A was $57.14M, beating the average forecast of $41.5M by 37.67%. Lastly, the company's EPS was $-3.04, beating the average prediction of $-1.573 by 93.20%